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Background and Objectives. Patients with aggressive
non-Hodgkin’s lymphomas (NHL) who do not obtain a com-
plete response (CR) after induction chemotherapy have a
poor prognosis. However, provided they are sensitive to the
first regimen of chemotherapy, 25-40% of them with a B-
cell phenotype may achieve long-term survival when treat-
ed with high dose chemotherapy and autologous stem cell
transplantation (HDC/ASCT). The aim of this study was to
analyze the efficacy of this therapy in the corresponding
patients with peripheral T-cell lymphoma (PTCL).
Design and Methods. We retrospectively evaluated the
efficacy of ASCT in 35 patients with PTCL from the GEL-
TAMO registry, who did not achieve a CR to standard induc-
tion chemotherapy regimens for aggressive NHL. Thirty-one
patients underwent transplantation after achieving a partial
response (PR) and 4 patients were non-responders.
Results. Following HDC/ASCT, 23 (66%) of the patients
achieved a CR, 4 (11%) a PR and in 7 (20%) cases the
transplant failed. One patient was not evaluated because of
early toxic death. With a median follow-up of the survivors
of 37.5 months, 18 patients (51%) are alive and 15
patients (43%) are free of disease. Transplant-related mor-
tality rate at 100 days was 11% and at 5 years the proba-
bilities of survival, freedom from progression and disease-
free survival for complete responders were 37%, 36% and
55% respectively. Pre-transplant lactate-dehydrogenase lev-
el, age-adjusted International Prognostic Index (aa-IPI) and
tumor score correlated with survival.
Interpretation and Conclusions. One third of the
patients with PTCL who fail to achieve CR to the first
chemotherapeutic regimen can be rescued with HDC/ASCT.
Pre-transplant values of IPI and tumor score risk systems for
aggressive lymphomas were useful to predict subsequent
survival.
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In adult patients, the majority of aggressive T-cellnon-Hodgkin's lymphomas (NHL) are peripheral T-cell lymphomas (PTCL).1 Indeed, excluding cutaneous,
lymphoblastic and adult T-cell leukemia/lymphoma,
PTCL constitute approximately 10% of NHL.2 No stan-
dard therapy has been established to treat this type of
lymphoma and usually,3-5 but not in all cases,6,7 when
standard therapeutic regimens for aggressive lym-
phomas are applied, the T-cell immunophenotype con-
fers a poor prognosis. However, results of salvage ther-
apies including high-dose chemotherapy and autolo-
gous stem cell transplantation (HDC/ASCT) seem to be
similar to those observed for the corresponding B-cell
immunophenotype.8-10
Failure to respond to induction therapy is defined as
not achieving a complete response (CR) to the first-line
therapy and represents a therapeutic challenge. Data
from corresponding B-cell lymphomas indicate that
approximately 40% of these patients can be salvaged
with HDC/ASCT.8,10,11 However, the efficacy of this ther-
apy in patients with PTCL in whom induction has failed
is less well defined. Recently, Kewalramini et al. report-
ed that patients with primary refractory PTCL treated
with HDC/ASCT respond in a similar manner to those
with a corresponding primary refractory aggressive B-
cell lymphoma.9 To investigate this possibility further,
we analyzed GEL-TAMO co-operative group patients
with PTCL who had not achieved a complete response
after induction chemotherapy and who then underwent
HDC/ASCT as a salvage therapy. Our data suggest that
patients with this type of lymphoma who fail to respond
to induction therapy, do indeed fare similarly to patients
with the corresponding aggressive B-cell lymphoma
when treated with HDC/ASCT.
Design and Methods
Patients
Between July 1990 and December 1999, the hospitals
participating in the Spanish Group for Lymphoma and
Autologous Transplantation (GEL-TAMO) treated 115
PTCL patients with HDC/ASCT. In this report we retro-
spectively selected the 35 (30%) patients from the reg-
istry who had failed to respond to first-line induction
treatment and who received HDC/ASCT as part of their
salvage treatment. The clinical characteristics of the
patients at diagnosis and at the time of transplantation
are set out in Table 1. Briefly, at diagnosis 47% of the
patients had an age-adjusted IPI (aa-IPI) score of 2 or
3. The maximal response to induction therapy in most
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patients [(31/35) (89%)] was only partial although
4/35 (11%) were refractory or the disease pro-
gressed during treatment. At the time of trans-
plantation, 43% of the patients had extranodal dis-
ease (14% bone marrow involvement). Most
patients (91%) had an ECOG performance status of
0-1 and 3% of the patients had one or more bulky
masses. High levels of β2-microglobulin and lac-
tate dehydrogenase (LDH) were detected in 45%
and 29% of the patients, respectively.
Therapy
The first-line and conditioning regimens for trans-
plantation are presented in Table 2. All patients
received standard induction regimens for aggres-
sive NHL (22 patients CHOP, 3 MegaCHOP, 6
patients MACOP-B and 3 patients ProMACE-
CYTABOM). A patient initially misdiagnosed with
Hodgkin’s disease received treatment with ABVD
and 2 patients received radiotherapy pretransplan-
tation. The median time from diagnosis to trans-
plantation was 7 months and the conditioning reg-
imens were based on BEAM or BEAC in 23 cases,
total body irradiation/cyclophosphamide in 6 and
other regimens in 6 patients.
Response assessment and follow-up
criteria
The response to therapy was evaluated 1, 3 and
6 months after transplantation and, thereafter,
every 6 months by the investigator responsible in
each center. Evaluation followed the standard
guidelines laid out by Cheson et al.12 Complete
response (CR) was defined as the disappearance of
ASCT in peripheral T-cell lymphoma after failed induction
Table 1. Clinical characteristics.
Variable At diagnosis At transplant
Sex (M/F) 20 (57%) 15 (43%)
Median age (range) 44 (14-65)
Ann Arbor Stage
I-II 5 (14%) 18 (51%)
III-IV 30 (86%) 17 (49%)
B-symptoms 11 (31%) 3 (9%)
Number of extranodal sites
0 12 (34%) 20 (57%)
1 12 (34%) 12 (34%)
>1 11 (32%) 3 (9%)
BM involvement 8 (23%) 5 (14%)
Bulky disease 11 (31%) 1 (3%)
ECOG > 1 10 (29%) 3 (9%)
High LDH 17 (51%) 10 (29%)
High β2M 10 (45%) 9 (45%)
Adjusted IPI
0-1 17 (53%) 25 (73%)
2-3 15 (47%) 9 (27%)
NA 3 1
Tumor score
0-2 15 (50%) 27 (84%)




MegaCHOP 3 (9%) − − 
Other 29%
BM, bone marrow; LDH, lactate dehydrogenase; β2M,
β2-microglobulin; NA, not available; CHOP, cyclophosphamide,
adriamycin, vincristine, prednisone. 
Table 2. Transplant-related factors.
Treatment characteristics
Disease status
Partial response 31 (89%)
Refractory 4 (11%)
Conditioning regimens








BM plus PB 3 (9%)
Median apheresis (range) 2 (1-6)






Treatment-related mortality 4 (11%)
Engraftment 35 (100%)
TBI: total-body irradiation; BEAM: carmustine, etoposide,
cytarabine, melphalan; BEAC: carmustine, etoposide, cytarabine,
cyclophosphamide; CVB: carmustine, etoposide,
cyclophosphamide; BM: bone marrow; PB: peripheral blood;
G-CSF: granulocyte colony-stimulating factor;
GM-CSF: granulocyte-macrophage colony-stimulating factor.
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all clinical evidence of lymphoma for a minimum of
4 weeks, with no persisting symptoms related to
the disease. Prior to transplantation a complete
restaging was performed in all patients. To cate-
gorize a patient as a complete responder after
transplantation, residual masses had to remain
unchanged for 6 months or longer.
A partial response (PR) was defined as a decrease
greater than 50% of the sum of the products of the
two longest diameters of all measurable lesions for
at least 4 weeks, and non-measurable lesions also
had to decrease by at least 50%. For patients to be
considered in this category no lesions could increase
in size and no new lesion could appear. A state of
progressive disease (PD) was defined as any increase
greater than 25% in the sum of the diameters of any
measurable lesions or the appearance of a new
lesion. We defined transplant-related mortality as
death within 100 days of HDC/ASCT not related to
the disease, relapse or progression. Standard vari-
ables to calculate the age-adjusted International
Prognostic Index13 and other variables of known
prognostic importance, such as the MD Anderson
tumor score,14 were evaluated at the time of diag-
nosis and transplantation.
Statistical methods
Overall survival (OS), freedom from progression
(FFP) and disease-free survival (DFS) were measured
from the date of transplantation, and were esti-
mated according to the Kaplan-Meier method.15
Comparisons between the variables of interest at
the time of transplantation were performed by the
log-rank test.16 All p-values reported were two-sided




Response to transplant was as follows: 66%
achieved a CR, 11% a PR, and in 20% of the cases
the treatment failed. The disease response was not
evaluated for 1 patient because of early death post-
transplantation. After a median follow-up of the
survivors of 37.5 months (range: 3-109), 18 patients
out of the 35 transplanted (51%) were alive and 15
(43%) showed no evidence of the disease. Of the 17
patients who died, 12 (71%) died from progressive
disease, 4 (24%) as a result of treatment-related
causes, and 1 patient died from a second neoplasia
while deemed to be free of lymphoma at this point.
The transplant-related mortality was 11% (2 cases
of adult respiratory distress syndrome, one sepsis,
and one hepatic veno-oclusive disease). The actuar-
ial OS at 5 years was 37% (95% confidence inter-
val (CI), 16% to 58%), the FFP was 36% (95% CI,
17% to 55%), and the DFS for complete responders
was 55% (95% CI, 30% to 80%: Figure 1).
Prognostic factors
Given the relatively small number of patients, we
only performed univariate analysis to investigate
which variables might be associated with the pos-
sible outcomes, including OS and FFP. We found
that 2 or 3 aa-IPI risk factors, a tumor score  >2,14
and an elevated LDH at the time of transplantation
were associated with reduced survival (Figure 2).
However, we could not identify any factor at trans-
plantation that provided prognostic information
with respect to FFP.
J. Rodriguez et al.
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Discussion
The most recent series5,17 of patients with
advanced stages of aggressive NHL treated with
standard protocols indicate that the T-cell
immunophenotype confers an unfavorable prog-
nosis, although similar outcomes were reported in
older smaller series.7 Patients with aggressive B-
cell lymphomas who fail to respond to a first induc-
tion regimen have an approximately 30% possibil-
ity of being functionally cured with HDC/ASCT.11,18
Nevertheless, whether this procedure is equally
effective in patients with PTCL is much less clear.
Recently, the Memorial group reported that they
obtained similar outcomes with HDC/ASCT treat-
ment in chemosensitive relapsed and primary
refractory patients with PTCL and diffuse large B-
cell lymphoma.9 Indeed, the 4-year survival of both
B- and T-cell groups were 46% and 34%, respec-
tively (p=0.418) and the FFP was 33% and 22%,
respectively (p=0.473). However only 7 patients in
the PTCL group were primary refractory to the ini-
tial therapy, raising doubts about the validity of
this effect.
Our data are from 35 patients with PTCL who
failed to respond to standard induction chemother-
apy for aggressive lymphomas, and who were reg-
istered in the GEL-TAMO database. Although most
of the patients were chemosensitive (31 patients
had had a first PR and only 4 were truly chemore-
sistant), the fact that 66% of these patients
achieved a CR following transplantation is a simi-
lar outcome to that in our cohort of 74 patients
with aggressive diffuse large B-cell lymphoma who
failed to respond to induction therapy and who
underwent HDC/ASCT.19 Interestingly we did not
observe significant differences in the OS, FFP and
DFS between the 22 patients who only achieved a
first PR but then obtained a CR following trans-
plantation and the 37 patients who initially
achieved a CR (unpublished data), suggesting that
when patients are chemosensitive, HDC/ASCT may
neutralize the adverse prognosis conferred by the
failure of first line induction therapy. These data
must be interpreted with caution since they are
derived from a retrospective study and randomized
prospective studies should be performed to evalu-
ate this point fully. Unfortunately, all the patients
with truly chemoresistant disease state failed to
respond to the transplant, emphasizing the need to
test other transplantation procedures or new ther-
apeutic strategies for this fortunately small group
of primary chemoresistant patients.
Our analysis showed that the aa-IPI and LDH at
the time of transplantation could serve as prog-
nostic factors for patients with this type of lym-
phoma. In our hands the tumor score14 was a very
useful means of separating patients with different
outcomes. Moreover, Lee et al.20 recently showed
ASCT in peripheral T-cell lymphoma after failed induction
Figure 2. Overall survival according to age-adjusted
International Prognostic Index, tumor score and lac-
tate dehydrogenase level.
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that the tumor score had a better discriminatory
value than that of the IPI in patients with early-
stage PTCL treated with doxorubicin-based chemo-
therapy, with or without radiotherapy. This sug-
gests that this risk system can be applied to this
group of lymphomas as it takes into consideration
the variables most related to the tumor rather than
the host. The tumor score includes β2-microglob-
ulin level as one of its variables, which is an impor-
tant prognostic variable across the whole group of
aggressive lymphomas, but which was not incor-
porated into the final analysis of the IPI project
because of the absence of data for a large number
of patients. Interestingly, more patients with PTCL
presented high levels of β2-microglobulin than did
those with corresponding aggressive B-cell lym-
phomas. No patient with more than two of the
tumor score factors survived in our group of
patients, another indication of the value of this risk
system.
In spite of the retrospective design of this study
and the limitations of a co-operative group registry,
we conclude that chemosensitive patients with
PTCL who fail to respond fully to induction seem to
benefit from HDC/ASCT. Within this group of
patients, those deemed to respond completely fol-
lowing the transplant have an excellent prognosis.
The aa-IPI, LDH and tumor score at the time of
transplantation were good means of predicting the
outcome in this population of patients. Neverthe-
less, it seems that patients who failed to achieve at
least a PR with front-line therapy did not benefit
from HDC/ASCT. New therapeutic options should
be tested in this small subset of patients. Finally,
the results obtained from this group of patients
with PTCL who failed to respond to induction do
not differ from those observed in larger groups of
patients with aggressive diffuse large B-cell lym-
phoma unresponsive to induction therapy.
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